Navigation Links
Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
Date:3/18/2008

CAMBRIDGE, Mass., March 18 /PRNewswire/ -- Peptimmune, Inc. a privately held biotechnology company, announced that it has completed its first clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PI-2301, a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.

The Phase I single ascending dose, double blind placebo controlled randomized study involved 56 healthy volunteers who received the drug in eight escalating dose cohorts. All doses were safe and well tolerated, and there were no serious adverse events. Pharmacodynamic assays demonstrated evidence of immune exposure consistent with the pharmacologic mechanism of action for PI-2301, and dose related pharmacokinetics were observed. The Company plans to initiate its first repeat dose study in multiple sclerosis patients in Q2/2008.

"We are pleased to see that PI-2301 was well tolerated and that this trial has provided evidence of single dose priming of healthy subjects. This effect is important as repeated doses in multiple sclerosis patients should lead to therapeutic immune modulation," stated Thomas P. Mathers, President and CEO of Peptimmune. "We have designed PI-2301 to maximize the therapeutic benefit of a proven, safe compound class in multiple sclerosis as well as increasing patients' convenience."

PI-2301 is a second generation peptide copolymer from a similar compound class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 works through immune modulation by enhancing the regulatory response of the immune system to control the pathogenic autoimmune response in certain diseases. PI-2301 has been optimized using Peptimmune's novel platform peptide chemistry and in pre- clinical studies, has shown to be more potent and effective than Copaxone in treating disease models for multiple sclerosis. PI-2301 has also shown efficacy in pre-clinical models of autoimmune diseases where immune modulation may be effe
'/>"/>

SOURCE Peptimmune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
2. NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
3. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
4. Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
5. NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
6. Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
7. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
8. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
9. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
10. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
11. Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... PARK, N.J. , July 30, 2015  Unichem ... voluntarily recalling one lot of Hydrochlorothiazide tablets 25 mg ... been initiated as a precautionary measure due to the ... of the product. The risk associated ... Hydrochlorothiazide tablet is the increased probability of experiencing Clopidogrel,s ...
(Date:7/30/2015)... July 30, 2015 PTC Therapeutics, Inc. (NASDAQ: ... reported financial results for the second quarter ending June ... many fronts across the organization.  We are excited to ... dystrophy clinical trial ever conducted with topline results expected ... Chief Executive Officer, PTC Therapeutics, Inc. "Translarna is now ...
(Date:7/30/2015)... , July 30, 2015  Cleveland Clinic President ... 2015 keynote address last month that industry is compelled ... order to gain the efficiencies—and develop the transformational innovations ... Dr. Barsoum,s comments were preceded by Doug Kohrs ... and OMTEC moderator, who stressed that industry must add ...
Breaking Medicine Technology:Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2
... MUNDELEIN, Ill. , July 1 ... and information systems developer, today announces executive changes in ...  John Kershaw, President & CEO, Sysmex America Inc. has ... Secretary; Judy Bosko as Vice President of ...
... SCHAUMBURG, Ill. , July 1 ... today announced that the U.S. Food and Drug Administration ... sodium injection, USP. Heparin is a vital anticoagulant, preventing ... within the blood, routinely used in surgical and dialysis ...
Cached Medicine Technology:Sysmex America Announces Executive Leadership Changes 2FDA Approves Sagent Pharmaceuticals' Heparin Sodium Injection, USP 2FDA Approves Sagent Pharmaceuticals' Heparin Sodium Injection, USP 3FDA Approves Sagent Pharmaceuticals' Heparin Sodium Injection, USP 4
(Date:8/1/2015)... CT (PRWEB) , ... August 01, 2015 , ... On March 19, 2015 Phil Valentine ... mile trek of the Appalachian Trail by stepping off Springer Mountain and heading ... , On July 26th Phil reached Connecticut and was greeted by friends and family. ...
(Date:7/31/2015)... CA (PRWEB) , ... August 01, 2015 , ... Super Bowl 50 will ... National Football League’s biggest day each year is the Super Bowl. In the two weeks ... takes place from the host venue. The 2016 Super Bowl game will mark the 50th ...
(Date:7/31/2015)... ... ... The 2nd annual Ride to Fight On will start and end near the ... to Fight On is a cycling fundraiser that benefits the West Cancer Center, a ... University of Tennessee Health Science Center. A health and wellness festival featuring food, music, ...
(Date:7/31/2015)... ... July 31, 2015 , ... Coco Libre announced today that their flagship ... at the 2015 Vans US Open of Surfing, July 25 through August 2 in ... added sugar” on the market, is a natural choice given the Open’s commitment to ...
(Date:7/31/2015)... ... , ... Well-known for its unique pastries and delicious confections, Pastry Palace, a ... making life just a little bit sweeter for newlyweds. A family-owned business, the Pastry ... one. , The bakery provides a full line of custom wedding cakes. Brides can ...
Breaking Medicine News(10 mins):Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2
... Inc. (Nasdaq: OSTE ), a leader in ... announced today that the Company,s fourth quarter and full ... released Wednesday, March 4, 2009. The management team of ... Thursday, March 5, 2009, at 9:00 a.m. (EST) to ...
... March 2 At Aurora Health Care , finding ... businesses that rely on the health care provider for health ... well-being of its own employees, and that commitment recently was ... its local affiliate the Wellness Council of Wisconsin, presented its ...
... March 2 Speaker Nancy Pelosi released the ... Kathleen Sebelius as Secretary of the Department of Health ... bipartisan leader who has worked to expand health care ... prescription drugs. "Governor Sebelius, deep understanding of health care ...
... March 2 Nitinol Devices & Components, Inc. ... novel medical device anchoring technology from Phase One ... This anchoring technology integrates the superelastic material properties ... provide secure fixation and removability for minimally invasive ...
... cites association on GMPs and adverse event reportingWASHINGTON, ... the U.S. Government Accountability Office (GAO) of a ... supplements, the Natural Products Association (NPA) released the ... Seckman."The Natural Products Association appreciates having the opportunity ...
... 2 /PRNewswire-Asia-FirstCall/ -- China Nepstar,Chain Drugstore Ltd. (NYSE: ... drugstore chain in China based on the number of ... the fourth quarter and,fiscal year 2008 financial results ended ... 16, 2009. , The Company ...
Cached Medicine News:Health News:Aurora Wins Gold Well Workplace Award for Commitment to Employee Health and Well-Being 2Health News:NDC Completes Acquisition of Phase One Medical(R) Anchoring Technology 2Health News:Natural Products Association Comments on New GAO Report on Regulation of Dietary Supplements 2Health News:China Nepstar Chain Drugstore to Announce Fourth Quarter and Fiscal 2008 Financial Results on March 16 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: